Pfizer · NSE: PFIZER · BSE: 500680
Q4 FY22 results · Jan–Mar 2022
Pfizer reported revenue from operations of ₹549.66 crore (up 2.8% from Q4 FY21) and net profit of ₹125.79 crore (up 25.1% from Q4 FY21) for Q4 FY22 (Jan–Mar 2022), on a standalone basis.
| Item | Q4 FY22 | Q4 FY21 | YoY | Q3 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 549.66 | 534.76 | +2.8% | 675.90 | −18.7% |
| Other income | 17.12 | 37.20 | −54.0% | 18.26 | −6.2% |
| Total income | 566.78 | 571.96 | −0.9% | 694.16 | −18.4% |
| Profit before tax | 145.11 | 132.09 | +9.9% | 184.09 | −21.2% |
| Net profit for the period | 125.79 | 100.55 | +25.1% | 143.91 | −12.6% |
| EPS, basic (₹) | 27.50 | 21.98 | +25.1% | 31.46 | −12.6% |
| Net margin (%) | 22.9 | 18.8 | 21.3 |
Standalone
- Filed with BSE
- 21 May 2022, 14:27 IST
- Board meeting
- 20 May 2022
- Period
- 01 Jan 2022 to 31 Mar 2022
- Review status
- Audited
- Source
- XBRL filing on BSE